Pemoline Treatment of Adolescents with Attention Deficit Hyperactivity Disorder: A Short-Term Controlled Trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite the increased recognition of attention deficit hyperactivity disorder (ADHD) in adolescents, few controlled studies have assessed treatments for this age group. Adolescent issues, such as embarrassment at receiving medication at school and experimentation with abusable substances, have accelerated efforts to find effective, well-tolerated treatments beyond traditional stimulants. Pemoline has been found effective for treating both children and adults with ADHD but has not been evaluated in adolescents with ADHD. METHODS: Twenty-one adolescents (mean age 14 years old) diagnosed with ADHD by structured and clinical interviews participated in a 10-week, double-blind crossover design study of pemoline. Dosing was optimized with robust doses up to 3 mg/kg/day in one to two doses. Clinical evaluations of ADHD, depression, anxiety, and oppositional defiant disorder (ODD) symptoms were assessed weekly. RESULTS: Adolescents with ADHD exhibited a marked response to pemoline treatment relative to placebo on the ADHD rating scale (p = 0.001), with an average reduction of 3.02 points per week of treatment. Sixty percent of adolescents responded to pemoline, compared to 11% treated with placebo. This response was independent of gender or lifetime psychiatric comorbidity. Pemoline was well tolerated, with patients averaging 2.88 mg/kg/day in two doses per day, with a mean dose at end of follow-up of 181.1 mg (SD 45.6, range 112.5-262.5 mg). Side effects were mild, and no adverse hepatic events occurred. CONCLUSIONS: These findings resemble those reported in children and adults with ADHD. This trial suggests pemoline is well tolerated and effective in adolescents and may be a particularly useful ADHD treatment for adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.5.564 · Cited by 1,738 · cited 1×
“ADHD (Biederman et al. 1991; Murphy and Barkley 1996; August et al. 1999).”
Self-citationHyperactive Boys Almost Grown Up: I. Psychiatric Status
Gittelman, R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330017002 · Cited by 977
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Self-citationBiederman, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090056010 · Cited by 771
Self-citationAttention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments
Murphy, K., & Barkley, R. A. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90022-x · Cited by 700 · cited 1×
“ADHD (Biederman et al. 1991; Murphy and Barkley 1996; August et al. 1999).”
Hyperactive Boys Almost Grown Up: V. Replication of Psychiatric Status
Mannuzza, S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250079012 · Cited by 549 · cited 2×
“PROSPECTIVE FOLLOW-UP STUDIES (Gittelman et al. 1985; Weiss and Hechtman 1993; Mannuzza et al. 1991; Biederman et al. 1996) and neuropsychology, familial aggregation, and neuroimaging evidence document the persistence of ADHD into adolescence and adulthood (Kovner et al.”
BIEDERMAN, J., FARAONE, S., MILBERGER, S., CURTIS, S., CHEN, L., MARRS, A., OUELLETTE, C., MOORE, P., & SPENCER, T. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199603000-00016 · Cited by 510
Self-citationSpencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402 · cited 1×
“To measure change during treatment, the following disorder-specific scales were used (Spencer et al. 1995; Wilens et al. 1999).”
Self-citationWender, P. H. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290083009 · Cited by 337
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1147 · Cited by 228 · cited 1×
“Improvement in our subjects continued through the 4 weeks of treatment, and longer treatment periods might have allowed greater benefit, as described with desipramine treatment of ADHD (Wilens et al. 1996; Spencer et al. 1993).”
Self-citationPELHAM, W. E., SWANSON, J. M., FURMAN, M. B., & SCHWINDT, H. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199511000-00018 · Cited by 81 · cited 1×
“Pemoline has a relatively long serum half-life of 11–13 hours in adolescents (Collier et al. 1985) and a behavioral half-life of 7 hours (Pelham et al. 1995), which allows daily or b.i.d. dosing.”
Cited by
CONNOR, D. F., GLATT, S. J., LOPEZ, I. D., JACKSON, D., & MELLONI, R. H. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200203000-00004 · Cited by 333
Comparing the efficacy of medications for ADHD using meta-analysis.
(2006) · PubMed Central · Cited by 230
Sibley, M. H., Kuriyan, A. B., Evans, S. W., Waxmonsky, J. G., & Smith, B. H. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.02.001 · Cited by 190
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Wilens, T. E., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., Stein, M. A., Conners, C. K., Duby, J., Newcorn, J., et al. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.1.82 · Cited by 160
Self-citation
Metadata
- Authors
- Bostic, J. Q., Biederman, J., Spencer, T. J., Wilens, T. E., Prince, J. B., Monuteaux, M. C., Sienna, M., Polisner, D. A., & Hatch, M.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2000-09
- Volume
- 10
- Issue
- 3
- Pages
- 205-216
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2074796593
- Cited by
- 32
- References
- 11
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.